cas 1825352-86-0|| where to buy 2,8-Dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine

Название продукции:2,8-Dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine

IUPAC Name:2,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine

: CAS：1825352-86-0; Молекулярная формула：C14H20BN3O2; Чистота：95%+

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM330195-1g	in stock	Ľưŉ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1825352-86-0 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:1825352-86-0; Молекулярная формула:C14H20BN3O2; Точка плавления:-; Smiles-код:CC1(C)C(C)(C)OB(C2=NN3C(C(C)=C2)=NC(C)=C3)O1; Плотность:

: Номер в каталоге:CM330195; Молекулярная масса:273.14; Точка кипения:; Номер Mdl:; Хранение:

: Imidazopyridazines; Potent IRAK-4 inhibitors have been reported by several groups including some structurally related benzimidazoles as well as alternative fused heterocycles such as the imidazopyridine and imidazopyridazine. Such compounds are reported to have IRAK-1 and IRAK-4 activity with varying degrees of selectivity.

: Risdiplam; As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.